TELA Bio, Inc. TELA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 79.91M | 80.81M | 80.28M | 77.06M | 75.32M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.91M | 80.81M | 80.28M | 77.06M | 75.32M |
| Cost of Revenue | 25.34M | 26.09M | 25.55M | 24.87M | 24.25M |
| Gross Profit | 54.57M | 54.73M | 54.72M | 52.19M | 51.08M |
| SG&A Expenses | 78.66M | 79.14M | 78.88M | 78.15M | 79.13M |
| Depreciation & Amortization | 380.00K | 380.00K | 380.00K | 380.00K | 380.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.92M | 114.62M | 114.03M | 112.52M | 112.60M |
| Operating Income | -34.01M | -33.81M | -33.76M | -35.46M | -37.27M |
| Income Before Tax | -40.91M | -39.60M | -38.60M | -39.06M | -40.83M |
| Income Tax Expenses | 265.00K | 238.00K | 230.00K | -59.00K | -59.00K |
| Earnings from Continuing Operations | -41.18 | -39.84 | -38.83 | -39.00 | -40.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.18M | -39.84M | -38.83M | -39.00M | -40.77M |
| EBIT | -34.01M | -33.81M | -33.76M | -35.46M | -37.27M |
| EBITDA | -33.01M | -32.80M | -32.75M | -34.41M | -36.21M |
| EPS Basic | -0.77 | -0.80 | -0.83 | -0.89 | -1.12 |
| Normalized Basic EPS | -0.47 | -0.48 | -0.51 | -0.56 | -0.70 |
| EPS Diluted | -0.77 | -0.80 | -0.83 | -0.89 | -1.12 |
| Normalized Diluted EPS | -0.47 | -0.48 | -0.51 | -0.56 | -0.70 |
| Average Basic Shares Outstanding | 211.78M | 199.73M | 187.74M | 176.13M | 155.41M |
| Average Diluted Shares Outstanding | 211.78M | 199.73M | 187.74M | 176.13M | 155.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |